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INTRODUCTION:
• Rasburicase is a costly medication, which is used to
treat high uric acid in tumor lysis syndrome
• Protocols for rasburicase dosing and dispensing are
vital for patient care
• This will help optimize treatment while not overusing
rasburicase

Standardized rasburicase protocols can
help cut down on waste and can help
avoid excessive rasburicase doses
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• Evaluate one rasburicase protocol at one
Intermountain Health Care hospital and
retrospectively apply this protocol to other hospitals
within the same health system to
evaluate rasburicase utilization
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making the time associated with these doses
difficult to evaluate.
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CONCLUSION: Cost per technician would be variable
based on salary.
• Standardized
rasburicase dosing can help cut down
on waste and help avoid excessive rasburicase doses
• Standardized uric acid lab draws can help
cut down on unnecessary lab draws and avoid the
cost associated
• Standardization starts with physician education
and the implementation of dosing and lab draw
protocols
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METHODS:
• Retrospective review of rasburicase doses
administered across Intermountain Healthcare over
one year
• Data included:
• Doses of rasburicase administered
• Dose recommended per protocol based on uric
acid level
• Time of uric acid levels were drawn
• Protocol that was utilized to evaluate the data set
recommended 3mg of rasburicase for patients
experiencing hyperuricemia, which was defined as
uric acid above 8mg/dL, or 6mg of rasburicase as an
initial dose if baseline uric acid was > 14mg/dL
• Recommended lab draw was 6 hours after
rasburicase administration followed by repeat doses
if uric acid levels were higher than 8mg/dL

RESULTS:
• A total of ninety-nine rasburicase doses
were evaluated
• Seventy-five doses (75.6%) were administered
off protocol, resulting in 210mg of
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additional
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• A total of $18.00
ninety-nine
per hours uric acid lab results
Time associated
with reconstitution
were reviewed
after initial
dose of vials
was approximately 1 hour
• Thirty-five
(35%)
were
drawn inappropriately
Number of events
of vials
reconstitution
would be 44 in the sample population
• The average
wholesale
price
(AWP)
Total cost for all encounters would be
of rasburicase
approximately
was$792.00.
$1,149.64 per 1.5mg
Total cost of vials with reconstitution is
• 210mg of$96,906.06
additional rasburicase dose
Complications with
numbers:
dispense calculated
to these
be $160,947
in extra hospital
Technicians would not be solely devoted
drug-related
costs
to reconstituting
these vials during that hour
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210 MG ADDITIONAL RASBURICASE DISPENSED
=

$160,947 EXTRA HOSPITAL DRUG-RELATED COSTS
*Authors can be contacted at parker.gundersen@student.roseman.edu. No conflicts of interests were reported by the authors.

DISCUSSION:
• Future directions include evaluating cost
of inappropriate lab draws and evaluating the use
of prophylactic rabsuricase doses (given at uric
acid <8mg/dL)
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